Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial

BACKGROUND: In recent years, there is increasing evidence showing a beneficial outcome (e.g. progression free survival; PFS) after metastases-directed therapy (MDT) with external beam radiotherapy (EBRT) or targeted surgery for oligometastatic hormone sensitive prostate cancer (oHSPC). However, many...

Descripción completa

Detalles Bibliográficos
Autores principales: Privé, Bastiaan M., Janssen, Marcel J. R., van Oort, Inge M., Muselaers, Constantijn H. J., Jonker, Marianne A., de Groot, Michel, Mehra, Niven, Verzijlbergen, J. Fred, Scheenen, Tom W. J., Zámecnik, Patrik, Barentsz, Jelle O., Gotthardt, Martin, Noordzij, Walter, Vogel, Wouter V., Bergman, Andries M., van der Poel, Henk G., Vis, André N., Oprea-Lager, Daniela E., Gerritsen, Winald R., Witjes, J. Alfred, Nagarajah, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490874/
https://www.ncbi.nlm.nih.gov/pubmed/32928177
http://dx.doi.org/10.1186/s12885-020-07386-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490874/
https://www.ncbi.nlm.nih.gov/pubmed/32928177
http://dx.doi.org/10.1186/s12885-020-07386-z

Ejemplares similares